Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in alzheimer's disease: Evidence from chemical cross-linking studies

D. E. Grigoriadis, B. G. Struble, D. L. Prica, B. B. De Sauza

Research output: Contribution to journalArticle

Abstract

Recent data have demonstrated that in Alzheimer's disease, the concentrations of corticotropin-releasing factor (CRF) were reduced and that there were reciprocal increases in CRF receptors in affected cerebrocortical areas. In order to determine whether the increases in CRF receptors in Alzheimer's disease were due to altered molecular composition of the binding protein, we compared the labeling pattern of 125I-Tyr0ovine CRF in temporal neocortex of Alzheimer's patients and age-matched controls using chemical cross-linking techniques. A similar pattern of 125I-Tyr0ovine CBF labeling was seen in Alzheimer's and control brains, with the major CRF binding protein corresponding to an apparent molecular weight of 58,000 Da. These data indicate that the increased CRF receptor population in cerebral cortex in Alzheimer's disease comprises bona fide CRF receptor binding subunits with no apparent change in the molecular structure.

Original languageEnglish (US)
Pages (from-to)761-764
Number of pages4
JournalNeuropharmacology
Volume28
Issue number7
DOIs
StatePublished - 1989

Fingerprint

Corticotropin-Releasing Hormone Receptors
Alzheimer Disease
Corticotropin-Releasing Hormone
Neocortex
Molecular Structure
Cerebral Cortex
Carrier Proteins
Molecular Weight
Brain
Population

Keywords

  • affinity cross-linking
  • Alzheimer's Disease
  • Corticotropin-Releasing Factor (CRF)
  • Receptors

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in alzheimer's disease : Evidence from chemical cross-linking studies. / Grigoriadis, D. E.; Struble, B. G.; Prica, D. L.; De Sauza, B. B.

In: Neuropharmacology, Vol. 28, No. 7, 1989, p. 761-764.

Research output: Contribution to journalArticle

@article{787884b216e348bf9d1e19fd65d12e68,
title = "Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in alzheimer's disease: Evidence from chemical cross-linking studies",
abstract = "Recent data have demonstrated that in Alzheimer's disease, the concentrations of corticotropin-releasing factor (CRF) were reduced and that there were reciprocal increases in CRF receptors in affected cerebrocortical areas. In order to determine whether the increases in CRF receptors in Alzheimer's disease were due to altered molecular composition of the binding protein, we compared the labeling pattern of 125I-Tyr0ovine CRF in temporal neocortex of Alzheimer's patients and age-matched controls using chemical cross-linking techniques. A similar pattern of 125I-Tyr0ovine CBF labeling was seen in Alzheimer's and control brains, with the major CRF binding protein corresponding to an apparent molecular weight of 58,000 Da. These data indicate that the increased CRF receptor population in cerebral cortex in Alzheimer's disease comprises bona fide CRF receptor binding subunits with no apparent change in the molecular structure.",
keywords = "affinity cross-linking, Alzheimer's Disease, Corticotropin-Releasing Factor (CRF), Receptors",
author = "Grigoriadis, {D. E.} and Struble, {B. G.} and Prica, {D. L.} and {De Sauza}, {B. B.}",
year = "1989",
doi = "10.1016/0028-3908(89)90164-0",
language = "English (US)",
volume = "28",
pages = "761--764",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in alzheimer's disease

T2 - Evidence from chemical cross-linking studies

AU - Grigoriadis, D. E.

AU - Struble, B. G.

AU - Prica, D. L.

AU - De Sauza, B. B.

PY - 1989

Y1 - 1989

N2 - Recent data have demonstrated that in Alzheimer's disease, the concentrations of corticotropin-releasing factor (CRF) were reduced and that there were reciprocal increases in CRF receptors in affected cerebrocortical areas. In order to determine whether the increases in CRF receptors in Alzheimer's disease were due to altered molecular composition of the binding protein, we compared the labeling pattern of 125I-Tyr0ovine CRF in temporal neocortex of Alzheimer's patients and age-matched controls using chemical cross-linking techniques. A similar pattern of 125I-Tyr0ovine CBF labeling was seen in Alzheimer's and control brains, with the major CRF binding protein corresponding to an apparent molecular weight of 58,000 Da. These data indicate that the increased CRF receptor population in cerebral cortex in Alzheimer's disease comprises bona fide CRF receptor binding subunits with no apparent change in the molecular structure.

AB - Recent data have demonstrated that in Alzheimer's disease, the concentrations of corticotropin-releasing factor (CRF) were reduced and that there were reciprocal increases in CRF receptors in affected cerebrocortical areas. In order to determine whether the increases in CRF receptors in Alzheimer's disease were due to altered molecular composition of the binding protein, we compared the labeling pattern of 125I-Tyr0ovine CRF in temporal neocortex of Alzheimer's patients and age-matched controls using chemical cross-linking techniques. A similar pattern of 125I-Tyr0ovine CBF labeling was seen in Alzheimer's and control brains, with the major CRF binding protein corresponding to an apparent molecular weight of 58,000 Da. These data indicate that the increased CRF receptor population in cerebral cortex in Alzheimer's disease comprises bona fide CRF receptor binding subunits with no apparent change in the molecular structure.

KW - affinity cross-linking

KW - Alzheimer's Disease

KW - Corticotropin-Releasing Factor (CRF)

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0024338774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024338774&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(89)90164-0

DO - 10.1016/0028-3908(89)90164-0

M3 - Article

C2 - 2548115

AN - SCOPUS:0024338774

VL - 28

SP - 761

EP - 764

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7

ER -